Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Japanese Journal of Clinical Oncology

• Publication date

  2013-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jjco/hyt096PMID 23888082
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy.

  2013cited by this paper
• Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project.

  2012cited by this paper
• Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project.

  2012cited by this paper
• Campbell-Walsh Urology

  2011cited by this paper
• Is metastasectomy for urothelial carcinoma worthwhile?

  2009cited by this paper
• Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05).

  2009cited by this paper
• Revised equations for estimated GFR from serum creatinine in Japan.

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Impact of multimodal treatment on survival in patients with metastatic urothelial cancer.

  2007cited by this paper
• Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

  2006cited by this paper
• Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report.

  2005cited by this paper
• Bladder cancer, the limits of surgical excision—when/how much?

  2001cited by this paper
• Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

  2000cited by this paper
• Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.

  1999cited by this paper
• Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

  1989cited by this paper
• Urothelial tumors of the upper urinary tract

  1985cited by this paper
• [Urothelial tumors of the upper urinary tract].

  1985cited by this paper
• International Agency for Research on Cancer.

  1968cited by this paper

• The first real-world evidence on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin followed by switch maintenance avelumab in advanced urothelial carcinoma: a propensity score-matched study

  2025cites this paper
• Do Fibroblast Growth Factor Receptor (FGFR) 2 and 3 Proteins Play a Role in Prognosis of Invasive Urothelial Bladder Carcinoma?

  2024cites this paper
• Physical, but not laboratory, treatment‐related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis

  2024cites this paper
• Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.

  2024cites this paper
• Survival of Metastatic Urothelial Carcinoma of Urinary Bladder According to Number and Location of Visceral Metastases.

  2024cites this paper
• Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review.

  2023cites this paper
• Evaluation of response to gemcitabine plus cisplatin-based chemotherapy using positron emission computed tomography for metastatic bladder cancer

  2023cites this paper
• Enfortumab vedotin versus platinum rechallenge in post‐platinum, post‐pembrolizumab advanced urothelial carcinoma: A multicenter propensity score‐matched study

  2023cites this paper
• Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab.

  2023cites this paper
• Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma

  2022cites this paper
• Improved survival in real‐world patients with advanced urothelial carcinoma: A multicenter propensity score‐matched cohort study comparing a period before the introduction of pembrolizumab (2003–2011) and a more recent period (2016–2020)

  2022cites this paper
• Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study

  2021cites this paper
• Characteristics and Management of a Cancer Patient with Stroke: A Case Report

  2021cites this paper
• The prognostic effect of metastasis patterns on overall survival in patients with distant metastatic bladder cancer: a SEER population-based analysis

  2021cites this paper
• Clinical Outcomes of Three or More Courses of First-line Chemotherapy for Metastatic Urothelial Carcinoma.

  2021cites this paper
• Role of Multimodal Treatment in Urothelial Carcinoma Spinal Metastasis: 15 Patients’ Experiences in a Single Center

  2020cites this paper
• Outcomes With Liver-Directed Therapy for Genitourinary Malignancies: Single-Institution Experience.

  2020cites this paper
• CMAR_A_258429 9003..9012

  2020cites this paper
• Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy

  2018cites this paper
• Metastatic Bladder Cancer

  2017cites this paper
• Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis

  2017cites this paper
• Oncologic Outcome of Metastasectomy for Urothelial Carcinoma: Who Is the Best Candidate?

  2017cites this paper
• Validation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world

  2016cites this paper
• Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin‐based chemotherapy

  2016cites this paper
• Female, Black, and Unmarried Patients Are More Likely to Present With Metastatic Bladder Urothelial Carcinoma.

  2016cites this paper
• Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder

  2016cites this paper
• Sarcopenia Evaluated Using the Skeletal Muscle Index Is a Significant Prognostic Factor for Metastatic Urothelial Carcinoma.

  2016cites this paper
• Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.

  2015cites this paper
• Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines

  2015cites this paper
• The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.

  2015cites this paper
• Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?

  2015cites this paper
• Comparing RECIST with EORTC criteria in metastatic bladder cancer

  2015cites this paper
• Pretreatment neutrophil‐to‐lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi‐institutional study

  2015cites this paper